IJBPAS, September, 2025, 14(9): 4868-4885

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

A REVIEW ON PHARMACEUTICAL APPLICATIONS OF PASTILLATION

KORNI RD*, NIKITHA N, SRAVANI T AND SAI LAKSHMI S

Raghu College of Pharmacy, Visakhapatnam, Andhra Pradesh

***Corresponding Author: Dr. Rama Devi Korni: E Mail: ramakalyank@gmail.com**

Received 15th April 2024; Revised 20th Aug. 2024; Accepted 15th Sept. 2024; Available online 1st Sept. 2025

https://doi.org/10.31032/IJBPAS/2025/14.9.9210

ABSTRACT

Pastilles are medications that dissolve in the mouth, formed of solidified liquid. The pastillation technique is a novel method that transforms bulk chemical liquid into solid, bead-like granules, making them ideal for bagging, shipping, and bulk material handling systems. Pastillation has been used to improve solubility of drugs, using high molecular weight, non-melting synthetic amorphous polymers that improve the solubility and dissolution rates of poorly water-soluble medicines. In situ coating is a process of applying a protective layer to a substrate, improving the functionality, stability, and performance of final particles. Pulsatile release dosage forms maximize drug distribution for better therapeutic results, allowing for regulated distribution, improved bioavailability, and customized drug release patterns. Controlled release systems, such as capsules, patches, or implants, play a crucial role in pharmaceuticals, agriculture, and other industries. Controlled release multiparticulate systems consist of several small drug depots, offering patients therapeutic benefits and greater product development flexibility. This study provides a new option for creating immediate and modified release drug delivery systems, replacing traditional tablets and capsules.

Keywords: Pastilles, Pastillation, Solubility enhancement, In situ coating, Pulsatile release, Controlled release

INTRODUCTION

Pastilles, which mean "a lump of meal or origin", is derived from the Latin pastilles, which is related to the word "bread" (panis). Originally, a pastille was a lump of crushed

herbs in the shape of a pill that was burned to release its therapeutic qualities. Pastilles are a kind of medication or sweet pill that are supposed to be taken by lightly chewing and letting them dissolve in the mouth. They are formed of a thick liquid that has been solidified. Another name for a pastille is a troche, which is a medicinal lozenge that dissolves like candy **[1]**. Pastillation technique is where bulk chemical liquid is transformed into solid, bead-like granules, or pastilles. They can be formed into specific sizes, shapes and consistencies according to customer needs. They are then often repackaged into bags or supersacks, and then prepared for storage or transport **[1]**. The growth of the chemical process sector has led to an increase in demands for the finished products' physical characteristics and overall quality. In order to regulate the rate at which drugs dissolve, the pharmaceutical industry has made extensive use of sophisticated tablet technology and coating using spray drying techniques. In order to produce a solid complex of pharmaceutical components, tableting processes are frequently employed. However, issues like rapid disintegration, side effects (excipient and binder), and instabilities still make the solid complex subpar. Here, a solidification technology is presented to aid in the solution of these issues. For example, to obtain the crystalline dosage form (pastilles), the pastillation method is used. This method distributes melts in a mono-size, dust-free, high-speed manner into scattered crystalline dosage forms. Drug delivery systems should be more stable and controlled when using crystalline-formed medications **[2]**. The first pastillation process to be developed was the ZN system, which was the precursor to the "DN" from KAISER and was created in 1953. The ZN system works on the drop forming concept, which is accomplished by the needle inside the nozzle moving up and down **[3]**.

Advantages

For the continuous conversion of molten goods into homogeneous, spherical, and dust-free granules that are perfect for bagging, shipping, and bulk material handling systems, pastillation offers a practical and economical method. Depending on the requirements and processing circumstances, the pastillation process can yield pastilles with diameters ranging from 1 to 25 mm and viscosities ranging from 5 to 30,000 mPas **[3]**. Minimizes cleanup in the event of a spill, provides easy storage, simplifies repackaging, appeals to a wider customer base, and improves safety. Additionally, the procedure facilitates easier handling, lowers labor expenses, and reduces waste **[1]**.

Disadvantages

This approach is especially useful for materials with low melting points, such as lipids, waxes, and macrogols, which melt and can resolidify at normal temperature. When using temperature to melt an excipient, the medicine being included must be thermally stable within the processing temperature range in order to prevent degradation during processing **[4]**.

Process Parameters of Pastillation

There are various parameters that need to be controlled during the process of pastillation like melting temperature of drug, roughness of crystallizer surface (Ra), dropping distance between surface and tip of pipette, degree of subcooling (ΔT), temperature of molten component, temperature of ambient air, density of drug, viscosity of molten drug, final impacting velocity, surface tension between air and molten drug, thermal conductivity of stainless steel and latent heat of drug **[5]**.

MANUFACTURING METHODS

The manufacturing methods are classified into two types: small scale and large scale. The fabrication technique and rollosizer mini come under small scale type; and ZN systems, GS system, rollomat and rollosizer come under large scale type

Fabrication Technique

An internal apparatus was created to produce pastilles on a laboratory scale **(Figure 1)**. The apparatus was made up of a 1.5 A transformer, a heating coil, a glass syringe with a stainless steel plunger, metallic hypodermic needles, and a metallic plate. An open-ended ceramic tube's exterior was wrapped with a heating coil, and it was insulated with a thick layer of ceramic clay. After that, the transformer and coil were connected before the electricity was turned on. The hypodermic needle-equipped syringe was placed within the ceramic tube. The burette folder was used to position this assemblage over the metallic plate. An ice cube in the ice tray plate beneath it aided to cool the metal plate. In order to ensure uniform drug distribution in the matrix, the drug and other necessary excipients were added to the lipid/PEG melt at temperatures between 140 - 150°C. The mixture was then manually stirred until a clear miscible mixture was produced. This was then poured into the preheated syringe and allowed to fall drop-wise pressure was manually controlled with the syringe's plunger onto the cold plate to create pastilles. A metallic scraper slightly sharp was used to scrape the pastilles once they solidified. After that, they were manually palced into size “0” capsules **[6]**.



Figure 1: Fabrication Technique

Rollosizer Mini

A small-scale steel belt cooler and corresponding Rotoform feeding device, comprising a stator, metering bar, rotating shell, refeed bar, and motor, serve as the foundation for the Rotoform MI granulation system **(Figure 2)**. Compressed air or inert gas is utilized to deliver the melt to the Rotoform MI system, where a needle valve ensures precise dosing onto the belt. Perfect synchronization between the steel belt cooler and feed is a feature shared by all Rotoform systems. Cold water is sprayed across the bottom of the steel belt to cool it down **[7]**.

Figure 2: Rollosizer Mini

ZN System

The ZN system works on the drop forming concept, which is accomplished by the needle inside the nozzle moving up and down **(Figure 3)**. The diameter of the nozzle and needle, the amount of liquid in the tub, and the number of needle strokes are the main factors influencing pastille size. Common products of ZN System are Acetanilide, Bisphenol A, Caustic soda, Fatty acids, Fatty alcohol, Disodiumtetrasulfide, Laurinlactam, Maleic anhydride, Monoglyceride, Neopenthylglycole, Paraffins, Pet food, Potassium soda, Succinic anhydride, TMA, TNT, TPP, Waxes, etc. **[3]**.



Figure 3: ZN System

GS System [Glocke /Stempel]

In contrast to the ZN method, a cylinder and piston combination takes the role of the needles **(Figure 4)**. The cylinder and piston's up and down motion enables the molten product to be deposited onto the belt, resulting in consistent pastilles. Products with medium to high viscosity have been designed for use with the GS system. Common products of GS System are Acetanilide, Bisphenol A, Caustic soda, Fatty acids, Fatty alcohol, Disodiumtetrasulfide, Laurinlactam, Maleic anhydride, Monoglyceride, Neopenthylglycole, Paraffins, Pet food, Potassium soda, Succinic anhydride, TMA, TNT, TPP, Waxes, etc. **[3]**.



Figure 4: GS System

Rollomat®

The Rollomat® rotary depositor functions on a similar concept to a gear pump. An inner-geared hollow cylinder with nozzles positioned in between the teeth is the central component of this system **(Figure 5)**. A pressing roll along the lower part of the hollow cylinder meshes with the teeth, feeding the product via the plug-in lance at the predetermined rate. It next travels onto the revolving pressing roll, where it is encased between the inner pressing roll and the outer cylinder. Product is forced through the nozzles and onto the cooling belt each time the teeth of the hollow cylinder make contact with the teeth of the pressing roll. When the cylinder reaches the drop-off point, the Rollomat®'s heated product scraper (refeed bar) makes sure it's exterior is clean. Common products of rollomat® are aluminium sulphate, Bitumen, Caprolactam, Castor oil, Chocolate, Chromic acid, Epoxy resin, Fertilizers, Ketonic resin, Modified stearic acid, Modified waxes, Petroleum resin, Phenolic resin, Polyamide resins, Polyester resins, Polyethylene waxes, PVC additives, Rosin resins, etc. **[3]**.



Figure 5: Rollomat

Rollosizer®

A static heated cylinder with an interior product channel and tubes for the heating medium is the basis of the drop-forming principle. The product enters the cooling belt through the perforations in the perforated outer cylinder using a unique product distribution bar **(Figure 6)**. The holes in the outer revolving cylinder and the holes in the product distribution bar overlap to create the pastilles. Immediately following the drop-forming, the product refeed bar gathers the excess material and forces it back into the openings of the outer revolving cylinder. Soft packings and easily replaceable o-rings are used to seal the product **[3]**.



Figure 6: Rollosizer

EVALUATION

Contact Angle Measurement

Using a photographic technique, the contact angle of the solidified hemispherical droplets, or pastilles, was measured against a solid stainless steel plate. Adobe Photoshop software was used to process and proportionally enlarge the photos. The following equation was used to confirm the angle of contact once it was manually determined and calculated mathematically:

$$\theta = tan^{-1}\frac{2h}{d}$$

where, d is the drop's diameter and h is its height from the plate

To get the contact angle, these two dimensions can be taken straight from the picture **[8]**.

Friability

After precisely weighing a sample of one gram of pastilles, it was put in the Roche friabilator's drum. The pastilles were taken out, cleaned, and precisely weighed after the drum was turned at 25 rpm for four minutes. The following formula was used to compute friability:

$$F(\%) = \frac{W0 - Wf}{W0} \times 100$$

where, W0 is the pastilles initial weight

Wf is their weight following the friability test **[8]**.

Assay

Pastilles containing required quantity of medication were added to distilled water and sonicated. The mentioned above solution was filtered using a 0.45 µm nylon filter, suitably diluted with distilled water, and subjected to spectrophotometric analysis at the proper wavelength **[8]**.

Drug Content Uniformity

To ensure consistent drug content, pastilles containing drug were placed each at a time into six dry volumetric flasks and processed further in accordance with the above-mentioned assay technique **[8]**.

Viscosity Measurement

A rotational viscometer was used to assess the viscosity of the pastillated mixtures because it affects the crystallization process and, consequently, a feasible separation. To achieve a homogenous mixture, several drug-polymer mixtures were continuously stirred while they melted. A temperature-controlled vessel was filled with the molten mixtures. The viscosities were measured at various shear rates depending on drug quantity **[9]**.

APPLICATIONS OF PASTILLATION IN PHARMACEUTICAL INDUSTRY

Solubility Enhancement

The pharmaceutical industry places great importance on the aqueous solubility of poorly soluble pharmaceuticals, as it plays a crucial role in the fate of recently created compounds. The research community has explored a number of solubility improvement methods, but the authors feel that what is really needed is a straightforward, affordable, and efficient method. Using high molecular weight, non-melting synthetic amorphous polymers by precipitation technology could effectively improve solubility. The authors achieved the desired properties of pharmaceutical formulations, such as acceptable hardness and friability, along with the enhancement of solubility and bioavailability by attending to various

formulation requirements, including the appropriate selection of plasticizers and overall composition.enhancement of solubility and bioavailability by attending to various formulation requirements, including the appropriate selection of plasticizers and overall composition **[10]**.

By using pastillation approach will increase the water solubility of ritonavir, a BCS class II anti-retroviral medication using EUDRAGIT® EP, an amorphous high molecular weight synthetic functional polymer. Using the DOE approach, the ratio of the constituents was investigated. Dissolve time and processability were examined as responses, while the amounts of the medication, polymer, and plasticizer were examined as independent variables. Through careful attention to different formulation requirements, including the appropriate selection of plasticizers and overall composition, the authors were able to attain the anticipated increases in solubility and bioavailability **[10]**.

Similarly the solubility of diclofenac sodium was improved by pastillation method using Kolliphor HS15. FTIR confirmed the formation of pastilles and the prepared pastilles were characterized for percentage yield, assay, solubility and dissolution test. The solubility was increased by 2-fold and dissolution rate was also enhanced by double than that of the drug **[11]**.

The solubility, dissolution rate, and bioavailability of weakly water-soluble medication atorvastatin was improved using solid lipid glycerol monostearate and surfactant poloxamer-407. Glycerol monostearate and poloxamer oral pastilles were created using the pastillation process, and central composite design was used to optimize them. The drug content, thermal characteristics, saturation solubility study, and in vitro, ex vivo, and in vivo drug release studies of hemispherical pastilles were all assessed. Formulation F4 demonstrated a 25-fold increase in solubility and a 3-fold increase in dissolution rate at high levels of glycerol monostearate (1000 mg) and poloxamer-407 (400 mg), respectively. The reduction in atorvastatin's crystallinity and the confirmation of its transformation from a crystalline to an amorphous state were demonstrated by X-ray diffraction and scanning electron microscopy, respectively. Ex vivo research showed that the highest quantity using poloxamer 407 as a surfactant and lipid GMS as a carrier, pastillation technique was successfully employed to increase the solubility and dissolution rate of the poorly water-soluble medication atorvastatin **[12]**.

In Situ Coating

An efficient, low-energy, and cost-effective method for incorporating various liquid quantities is in situ encapsulation. It incorporates a novel encapsulation method with the well-known pastillation and crystallization procedures. The end products are made up of a liquid core and a crystalline shell, albeit the liquid's volume and the size of the capsules can change. Just a small number of process requirements need to be met. It is necessary for the shell material to dissolve in the liquid, or for the shell and core materials to dissolve in the same solvent. The capsules will therefore have a liquid core and a crystalline exterior. This brand-new, cutting-edge encapsulating method hasn't been used yet **[13]**.

The coated tablets of ibuprofen were prepared in a single step by using the technology of melt crystallization. This technology enables the in situ separation of two components (coating material and active ingredient) based on a pastillation process. The existence of a eutectic point in the phase diagram and the thermophysical characteristics of the materials utilized determine how this technology is designed and applied. The eutectic point (30 mass% of ibuprofen, 52 °C) was identified by DSC curves and phase diagram. Next, using thermogravimetric analysis, the stability of the chosen mixture (10:90 mass% of ibuprofen, PEG6000) was investigated. Lastly, the coating quality was examined in various operating scenarios, such as viscosity, temperature of the cooling plate, ultrasonic power, and seeding. This parametric investigation demonstrated that in order to produce a hemispherical pastille, seeding with PEG6000 is required. It was feasible to identify the ideal viscosity and cooling plate temperature (271.77 mPas, 25°C) in addition to optimizing the in-situ coating process's operating parameters in order to produce a homogeneous and crystalline covering **[14]**.

Demonstrated the in situ encapsulation procedure using three xylitol capsules each with a different content and size. It might be demonstrated that figuring out the ideal production circumstances requires knowledge of the components' solubility. The temperature throughout the process and the administration of seed crystals has a significant impact on the quality of the capsules. An unstable shell is produced when the capsules crystallize quickly. However, the crushing force required to shatter the capsules is also growing as the shell's layer thickness increases **[13]**.

In situ coating technology was used to create pediatric-use paracetamol-containing pastilles

from a eutectic of two sugar alcohols (xylitol and sorbitol) in a single process. Compared to other traditional tableting technologies, where the production of the pastilles and their coating take place during the same fabrication process, this kind of melt technology is more affordable and easier to use. The pastilles were created with a softer center and with a single chilling phase, a more durable shell. By adding polyethylene glycol (PEG) 2000 or 6000 to the eutectic containing paracetamol, the rate of paracetamol dissolution may be significantly boosted. This is especially true when using PEG 2000, which would result in equal dissolving characteristics under conditions that are specific to the stomach and mouth **[15]**.

Evaluated the potential of in situ coating as a substitute coating technique by preparing pastilles made of xylitol and isomalt. Pastilles composed of a xylitol-isomalt melt were crystallized using the traditional methods of seeding and ultrasonic treatment. The manufactured pastilles have a glassy core and a crystalline hard shell that may be seen in tiny cross-section pictures **[9].**

Pulsatile Release

Pulsatile drug delivery has a significant role in chronotherapeutics which are formulated to release drug immediately after a lag time of no-drug release. These dosage forms are used for treating diseases which show circadian rhythms in their pathophysiology. They are also used for avoiding acid degradation of drug in stomach, avoiding pharmacokinetic drug—drug interactions, avoiding the development of resistance to certain drugs such as isosorbide nitrate. Multiunit pulsatile dosage forms have the advantage of uniform gastrointestinal transit when compared to single unit dosage forms **[8]**.

Pastillation technology has been applied to create a multilayered doxofylline dosage form for the chronotherapeutic treatment of nocturnal asthma. The medication, polyethylene glycol 4000, and colloidal silicon dioxide were combined to form pastilles, which were produced utilizing a laboratory-scale pastillation apparatus onsite. Using a standard coater, the pastilles were further coated with a floating layer and enteric polymers. The pastilles underwent in vitro drug release investigations, in vivo pharmacokinetic tests in rats, physicochemical analysis, and morphological characterization. The enteric-coated (10% w/w) pastilles were found to have adequate acid resistance when the drug was released, but the uncoated pastilles released the medication instantly. The prepared formulation showed a lag time of approximately 5 h in drug release, which

would be instrumental in achieving effective plasma drug concentration in early morning hours (03.00 -- 06.00 h) if the dosage form is administered at 22.00 h last night. Thus, the treatment is expected to prevent the onset of asthmatic attack in the morning and reduce the chances of awakening and discomfort to the patient **[8]**.

Controlled Release and Sustained Release

Oral controlled release medication delivery systems are the most widely used dose forms for long-term therapy. These systems have numerous benefits, including essentially constant drug levels at the site of action, minimal peak-valley fluctuations, drug dosage reduction, decreased dosage frequency, avoidance of side effects, and increased patient compliance. They also release the drug at a steady rate. The drug concentration is kept in the therapeutic window for an extended amount of time (sustained release) in these formulations, which exhibits a characteristic pattern of drug release and guarantees sustained therapeutic effect. A controlled release multi particulate system is made up of several small drug depots where the medication is either contained in a reservoir or distributed throughout a matrix. Their sizes vary .It could be millimeter to nanoscale in nature. They can be given in a single dosage by compressing into a dispersible tablet or, in the event of a high dose, filling into a capsule or sachet. They are commonly referred to as nanoparticles, micro particles, microcapsules, pellets, mini tablets, and granules. They can be produced by employing the proper processing techniques and tools to aggregate finely ground drug ingredient and excipient powders or granules **[4]**.

When compared to traditional tablets, spheroidal particles have some benefits in terms of pharmacokinetics and biopharmaceutics. The goal of the project was to create spheroidal pastilles with prolonged release via a brand-new single-step pastillation technique. The goal was to use the Low Density Bed Deposition (LDBD) technology to create the novel anionic methacrylate copolymer EUDRAGIT® FS 100 and the BCS class I antihypertensive medication metoprolol succinate. For solidification and spheronization, Aerosil® 200 was employed as a deposition bed. The pastilles that were optimized exhibited favorable physical qualities, excellent sphericity, processability, and sustained release characteristics. The drug's amorphous conversion was demonstrated by DSC and XRD data, which improved the pastilles' release properties. The study showed compelling evidence that spheroidal

functional particles for pharmaceutical formulations may be produced in a single stage of production using straightforward yet efficient adjustments to economically and practically feasible manufacturing procedures, such as pastillation **[16]**.

Examining solid lipids as a polymer substitute in the formulation of oral modified-release pastilles was the main objective of Ahire's work. Since ancient times, lipids have been utilized in medicines for a number of reasons. They are employed in the creation of dosage forms as polymer replacements. Lipids are used in the solvent-free pastillation process to create the modified-release oral dosage form that is the subject of this investigation. A 2^3-factorial design in Minitab was used to optimize the melt solidification equipment, which was created at the laboratory scale to create hemispherical-shaped pastilles utilizing solid lipid stearic acid. At the 2-level, three factors - X1 needle gauge, X2 falling height, and X3 base plate temperature - were taken into account and investigated **[17]**.

The solid lipid glycerol monostearate were also designed to regulate the release of the medication metoprolol succinate, which is very soluble in water. The device was calibrated with a 14G needle size and a 4°C-cooled metallic surface base plate. The size, shape, contact angle, density, flow characteristics, friability, crushing strength, drug content, temperature characteristics, and in vitro and in vivo drug release of pastilles were assessed. The patties had a hemispherical form and measured between 3.1 and 4.3 mm. More than 120 degrees was discovered to be the contact angle. Drug release was regulated for eight hours. A study using scanning electron microscopy showed that the drug release was enhanced by the smooth exterior surface with pores allowing dissolving solutions to enter. The dissolution rate was increased with more pore former. It was discovered that other operational factors, such as contact angle and needle height from base plate, had an impact on pastille size. The first order kinetic model provided the greatest fit for the optimized batch of pastilles' dissolution. A correlation was seen between the in vitro drug release profile and the in vivo pharmacokinetic studies. It is discovered that apparatus is affordable for small-scale technologies. It has been discovered that potassium chloride is an effective pore forming to improve medication release from lipid-based pastilles. Therefore, this is a flexible and promising method for the formulation of oral lipid-based multiparticulate controlled release **[18]**.

The pharmacokinetic and gamma scintigraphic imaging in vivo investigation

validates that the pulsatile release formulations of Doxofylline may release the medicine only after a predetermined amount of time, which is specifically needed to treat nocturnal asthma. The in vitro drug release investigation, which shows the effectiveness of the coating system, and these results concur. This study provides a new option for replacing traditional tablets and capsules by confirming the potential of PEG 4000 based pastilles to function as quick release dosage forms. By adding more suitable polymer coating to these dosage forms, it is possible to greatly enhance their functional characteristics and regulate the drug's release in a predefined way. In continuation of this research, a reservoir-based controlled release formulation can be created by coating the immediate release pastilles with extended release polymers **[19]**.

Pastillation was used to create lipid-based oral multiparticulate controlled release dosage forms by Dali Shukla for the first time in the pharmaceutical industry. A device designed for internal use on a laboratory scale produced doxofylline-loaded stearic acid pastilles by using PEG 4000, PEG 6000, and PEG 400. The drug content uniformity, drug release profile, morphology, and contact angle of the produced pastilles were all evaluated. The ideal pastillation settings were a 1.00 cm falling height, a 20 G needle orifice, and a 4 °C plate temperature. These results produced good pastilles with a contact angle over 90° and a uniform size of 2.5–3.0 mm. This multiparticulate system can sustain the drug release for a full day and has excellent flow properties. It is also highly consistent in size, weight, and drug content.

Comparing this technology to other current procedures (melt-extrusion and freeze-pelletization), which can then be filled in capsules or sachets, lipid-based multi-particulate systems are produced in a much simpler manner. The primary benefit of this technology is the well-established use of large-scale pastillation equipment in the chemical industry. Utilizing this special dosage form could therefore lead to new opportunities in the field of medication administration, including line extensions and the creation of patent-compliant versions of current formulations **[4]**.

Table 1: Applications of pastillation

Application	Drug	Polymer	Result	Reference
Solubility Enhancement	Ritonavir	EUDRAGIT® EPO, PEG 6000, Stearic acid	The release of the drug from pastilles was found to be around 80% compared to 35% of bulk ritonavir.	[10]
	Diclofenac sodium	Kolliphor HS15	The saturation concentration of Diclofenac sodium in water was found to	[11]

			be 17.89 µg/mL. This was almost 52.93% increment of solubility	
	Atorvastatin	Poloxamer-407, Glycerol monostearate	Formulation at high level of glycerolmonostearate (1000 mg) and poloxamer-407 (400 mg) showed 25-fold and 3-fold increased in solubility anddissolution rate, respectively.	[12]
In situ coating	Ibuprofen	PEG 6000	For the ibuprofen – PEG 6000 mixture studied here, the phase diagram reveals a eutectic point at 30 mass% ibuprofen. In situ coating via melt crystallization technology is feasible for the production of coated ibuprofen tablets.	[14]
	Xylitol	Ascorbic acid	The ascorbic acid system has the highest solubility at the temperature. That means that more xylitol is dissolved in the liquid core and less crystallized in the shell which results in the lowest layer thickness.	[13]
	Paracetamol (PCT)	PEG 2000, PEG 6000	Adding polyethylene glycol (PEG) 2000 or 6000 to the PCT-containing eutectic, the dissolution rate of PCT could be considerably increased, especially when using PEG 2000, reaching equal dissolution characteristics both under mouth- and gastric-specific conditions.	[15]
	Xylitol	Isomalt	Pastilles made of mixtures with less xylitol, an ultrasound treatment is necessary to initiate nucleation where an additional seeding enhances the crystallization of the pastille bottom.	[9]
Pulsatile Release	Doxofylline	PEG 4000,	Formulation showed a lag time of approximately 5 h in drug release, which would be instrumental in achieving effective plasma drug concentration in early morning hours if the dosage form is administered at 22.00 h last night.	[8]
Controlled Release	Metoprolol succinate	EUDRAGIT® FS 100, PEG 6000	It appears that optimal ratio the polymer, EUDRAGIT® FS 100 and the plasticizer has significant role in ensuring end release of drug from pastilles by following zero order kinetics.	[16]
	Metformin hydrochloride	Stearic acid, PEG 4000, PEG 6000, Poloxamer 407	PEG 6000 has a higher molecular weight than PEG 4000, leading to comparably larger channels. Approximately 30% of the drug was generally released in the first two hours, and only in the case of PEG 6000 was there a sustained release, with more than 90% of the drug released in the next twelve hours. A batch that was optimized (Poloxomer407) adhered to the first-order drug release kinetic model.	[17]
	Metoprolol Succinate	Glycerol monostearate, Potassium chloride	The observed tmax and Cmax are 1 h and 759.54 ± 18.55 ng/mL respectively. The Cmax of pastille was high enough within 1 h. This suggested the drug released and absorbed within1h. Further drug release was controlled.	[18]
	Doxofylline	Stearic acid, Benefat,	The pastilles coated with the enteric coat and the additional floating coat were	[19]

		PEG 4000	**effective in significantly delaying the in vivo drug release of having lag time of 4-5 h required for the chronotherapeutic treatment of nocturnal asthma.**	
	Doxofylline	**Stearic acid, Benefat, Pore formers - PEG 4000, PEG 6000, PEG 400**	**PEG 400 being in the liquid state is homogenously distributed throughout the matrix. The faster drug release rate of PEG 6000 than PEG 4000 as molecular weight of PEG 6000 is higher than PEG 4000 which results in comparatively bigger channels. Overall, about ≤30% of drug was released in two hours after which controlled release with more than 90% drug release in 24 hrs was achieved only in case of PEG 6000.**	**[4]**

CONCLUSION

Since pastillation allows for the continuous production of solid dosage forms without compromising product quality, it is the method that has the lowest overall cost. It is hence the preferred approach. The study's findings gave rise to the deduction that the newly created release retardant and dose form might both be regarded as economically advantageous. The investigation's results, which were discovered throughout, directly led to the conclusion that was reached. This decision was made as a direct consequence of the conclusions that emerged during the investigation, and it was a direct outcome of those conclusions.

The investigation's findings led to the conclusion that it has the potential for industrial application and scalability because it allowed for continuous manufacture. The results led to the conclusion that was made. The conclusions that emerged from the study directly led to the decision that was made. The study's findings directly led to the formation of this conclusion, which was reached as a consequence of those findings. The least expensive method for continuously producing solid dosage forms without sacrificing product quality is pastillation. The study's findings indicated that the newly created dosage form and release retardant were determined to be economically viable. The study's conclusion was that because it provided continuous manufacturing, it had scalability and industrial applicability.

REFERENCES:-

[1] Dhoom AD, Bhagariya AJ, Saharya NG, Pawar JA, Vagh SL. Novel Techniques for continues manufacturing process: Pastillation. Journal of Emerging Technologies and Innovative Research (JETIR), 2022; 9.

[2] Kim JW, Cheon YH, Donchev D, Kim SH, Ulrich J. Investigation of entrapped pore in the pastilles by a mercury porosimetery technique. International Journal of Pharmaceutics, 2005; 288: 305–314.

[3] http://kaiser-pbt.de/en/services/process-technologies/pastillation/

[4] Shukla D, Chakraborty S, Sanjay S, Mishra B. Pastillation: A novel technology for development of oral lipid based multiparticulate controlled release formulation. Powder Technology, 2011; 209: 65–72.

[5] Kim JW, Ulrich J. Prediction of degree of deformation and crystallization time of molten droplets in pastillation process. International Journal of Pharmaceutics,2003; 257: 205–215.

[6] Kumar A, Seema, Neha SL, Kumar S. A detailed review on methods, evaluation and limitations of Pastillation process. Eur. Chem. Bull,2023; 12: 1668-1682.

[7] http://ipco.com/products/rotoform-granulation-systems/

[8] Shukla D, Chakraborty S, Mishra B. In vitro and in vivo evaluation of multilayered pastilles for chronotherapeutic management of nocturnal asthma. Expert Opinion Drug Deliv,2012; 9.

[9] Wendt K, Petersen S, Ulrich J. Application of In Situ Coating on a Two-Compound System. Chemical Engineering Technology,2014; 37: 1408–1412.

[10] GuhaA, Bhalekar M, Madgulkar A, Ingale A. Pastillation with amorphous synthetic polymers: A key to solubility enhancement of poorly soluble drugs. Pharmacophore,2022; 13(6) : 70-76.

[11] Sopan P, Nilesh M, Purushottam G, Amol W. Enhancement of Solubility of Diclofenac Sodium by Pastillation Method. Journal of Drug Delivery and Therapeutics, 2021;11: 6-10.

[12] Pandit AP, Chavan TT, Khandelwal KR. Enhancement of solubility, dissolution rate and bioavailability of atorvastatin using solid lipid: in vitro and in vivo characterization. Journal of Pharmaceutical Investigation, 2015.

[13] Hartwig A, Ulrich J. In situ encapsulation of liquids by means of crystallization. Journal of Crystal Growth,2017;469: 128–130.

[14] Mameri F, Koutchoukali O, Koutchoukali MS, Hartwig A,

Nemdili L, Ulrich J. Optimum operating conditions for manufacturing ibuprofen tablets coated with polyethylene glycol by melt crystallization process. Journal of Thermal Analysis and Calorimetry, 2018.

[15] Katona G, Szalontai B, Budai-Szűcs M, Csányi E, Szabó-Révész P, Jójárt-Laczkovich O. Formulation of paracetamol-containing pastilles with in situ coating technology. European Journal of Pharmaceutical Sciences,2016.

[16] GuhaA, Bhalekar M, Madgulkar A. Sustained Release Spheroidal Pastilles Using Novel Low Density Bed Deposition Technology. International Journal of Pharmaceutical research and Applications,2023; 8(4): 443-451.

[17] Ahire SB, Kamble RK. Design and Development of Modified Release Dosage Form of BCS Class-III Drug by Novel Pastillation Technique. International Journal of Pharmaceutical Sciences and Research,2023; 14: 3913-3924.

[18] Pandit AP, Divase G, Chavan T, Khandelwal K. Oral lipid based multiparticulate pastilles: design and effect of pore former. Journal of Pharmaceutical Investigation, 2014.

[19] Shukla D, Chakraborty S, Mishra B. Evaluation of in vivo behavior of controlled and pulsatile release pastilles using pharmacokinetic and gamma-scintigraphic techniques. Expert Opinion Drug Deliv,2012; 9.